Last hope? new combo targets tough hepatitis c cases
NCT ID NCT01468584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the virus from the body for good. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
- What this could lead to
- If successful, this could offer a new treatment option for people with genotype 2 hepatitis C who did not get better with previous therapy.
- What could go wrong
- This is a very small study (only 10 people) and results may not apply to larger groups. The drug combination can cause side effects like anemia and depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users
- New hope: hepatitis c drugs after liver cancer treatment